Body Protection Compound-157: Discovery, mechanism, and clinical context
⚠️ Informational Purposes Only
This content is for educational and research purposes only. BPC-157 is not FDA-approved for human use. Always consult qualified healthcare providers for medical decisions.
Pharmacokinetics
~4-6 hr half-life
Origin
Gastric protein
FDA Status
Not approved
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It was first isolated and studied for its role in gastric mucosal defense mechanisms. The compound has been the subject of extensive in vitro and animal research since the 1990s, though it has not undergone formal human clinical trials required for FDA approval.
Research suggests BPC-157 influences several biological pathways:
The majority of BPC-157 research has been conducted in rodent models. Studies have investigated effects on:
Note: Animal study results do not predict human outcomes.
As of 2025, no peer-reviewed, placebo-controlled human clinical trials of BPC-157 have been published in major medical journals. The compound remains classified as a research chemical, and any human use occurs outside approved clinical trial frameworks. This lack of human safety and efficacy data is a significant limitation in assessing the compound's therapeutic potential.
United States (FDA): BPC-157 is not approved by the FDA for any medical indication. It is not classified as a drug, supplement, or food additive. The FDA has not evaluated its safety or efficacy in humans.
World Anti-Doping Agency (WADA): As of 2024, BPC-157 is not explicitly listed on the WADA Prohibited List, though it may fall under the general category of "non-approved substances." Athletes should consult current WADA guidance.
Compounding Pharmacy: Following FDA warnings in 2023-2024 regarding compounded peptides, the regulatory landscape for BPC-157 access through compounding pharmacies has become increasingly restricted.
Available pharmacokinetic data is primarily from animal studies:
| Parameter | Rodent Data | Notes |
|---|---|---|
| Elimination half-life | ~4-6 hours | IV administration in rats |
| Bioavailability (oral) | <1% | Extensive first-pass metabolism |
| Stability | Stable in gastric juice | Unique among peptides |
For researchers and clinicians tracking BPC-157 administration in approved research settings, Jabbit provides data management tools with pharmacokinetic visualization based on published literature.
Track research compounds with Jabbit's privacy-first toolkit
Download on App Store